How to Buy Kiniksa Pharmaceuticals International Stock
Kiniksa Pharmaceuticals International PLC
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Kiniksa Pharmaceuticals International stock last closed at $92.24, down 5.45% from the previous day, and has increased 147.36% in one year. It has overperformed other stocks in the Biotechnology industry by 2.14 percentage points. Kiniksa Pharmaceuticals International stock is currently +152.3% from its 52-week low of $36.56, and -6.34% from its 52-week high of $98.48.
At the moment, there are 78.57M KNSA shares outstanding. The market value of KNSA is $7.25B. In the last 24 hours, 1.32M KNSA shares were traded.
How to Buy Kiniksa Pharmaceuticals International Stock
Not sure how to invest in Kiniksa Pharmaceuticals International stock? Here's how.
- Choose where to buy Kiniksa Pharmaceuticals International stock: You need to choose an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you determine where to buy Kiniksa Pharmaceuticals International stock.
- Open your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit money your investment account: Select your payment method and add your details.
- Evaluate Kiniksa Pharmaceuticals International stock: The Kiniksa Pharmaceuticals International ticker symbol is KNSA. Is Kiniksa Pharmaceuticals International stock a good investment? Should you buy shares of KNSA? How do KNSA's underlying business fundamentals look? Do top analysts think Kiniksa Pharmaceuticals International is a good buy? Why has KNSA's stock price moved recently? (Hint: Our stock analysis website can help you understand if KNSA is a good stock to buy).
- Place your KNSA purchase: Decide if you will purchase KNSA shares at the current market price or use a limit order to buy KNSA shares at a given price.
- Keep tabs on your KNSA investment: Create a watchlist to important notifications about your position in Kiniksa Pharmaceuticals International stock.
Step 1: Choose where to buy Kiniksa Pharmaceuticals International stock
You will need a brokerage account in order to access the NASDAQ market and buy KNSA stock.
Our favorite brokerage: eToro
Based on our research, eToro is the best stock brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world markets: From Technology to Industrials, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro boasts a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've selected the right brokerage, you need to fill out some personal information so you are able to invest in KNSA stock today.
How to Open a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to create your new trading account.
- Send your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've filled out your info on stock market apps, you can securely and quickly fund your account:
Watch the video below to see the process of depositing money into your new brokerage account.
Step 4: Evaluate Kiniksa Pharmaceuticals International stock
After you have chosen the best place to buy Kiniksa Pharmaceuticals International stock, it's critical to analyze their stock prior to buying, so you can understand the risk as well as the opportunity.
Kiniksa Pharmaceuticals International shares quick numbers
Fundamentals of KNSA
WallStreetZen was designed to help part-time investors do better fundamental analysis quickly.
You can see all of the due diligence checks on KNSA's stock page.
Is KNSA stock undervalued?
Analysts use many financial metrics, analyses, models, and charts to gauge KNSA's intrinsic value.
Using relative valuations methods:
- KNSA could be overvalued based on its P/E ratio of 64.5x, relative to Biotechnology industry P/E ratio of 16.38x
- KNSA could be overvalued based on its P/B ratio of 10.2x, relative to Biotechnology industry P/B ratio of 5.17x
- KNSA could be overvalued based on its PEG ratio of 2.96x
You can do additional valuation research on KNSA's stock here.
Is KNSA a healthy company?
Signs that KNSA is financially healthy:
- KNSA has a low debt to equity ratio of 0.38.
- There are more short-term assets than short-term liabilities on the KNSA balance sheet.
- KNSA profit margin has gone up from 6% to 11.6% in the past year.
- There are more short-term assets than long-term liabilities on the KNSA balance sheet.
- KNSA's operating cash flow of $198.84M allows it to safely service it's debt of $7.88M.
- KNSA earnings of $146.15M is not enough to cover its interest payments.
Signs that KNSA is not financially healthy:
- Total KNSA debt is higher than 5 years ago, relative to shareholder equity.
Is KNSA stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 7 Equities analysts who monitor KNSA, the consensus analyst rating on Kiniksa Pharmaceuticals International is a Strong Buy
It's important to note that analyst ratings are not recommendations, nor are they financial advice.
Most Recent KNSA Analyst Recommendations
Geoff Meacham, a top 7% analyst from Citigroup maintains KNSA with a strong buy rating and raises their KNSA price target from $60.00 to $100.00, on Jul 29, 2026.
Citigroup's Geoff Meacham raised their price target on Kiniksa Pharmaceuticals International (NASDAQ: KNSA) by 66.7% from $60 to $100 on 2026/07/29. The analyst maintained their Strong Buy rating on the stock.
Kiniksa Pharmaceuticals International reported its Q2 2026 earnings.
Meacham described the print as "robust."
According to the analyst, Arcalyst's commercial durability is on the rise, and Kiniksa Pharmaceuticals International is making progress toward a multi-asset commercial franchise.
Earnings Report
For Q2 2026, Kiniksa Pharmaceuticals International reported:
- EPS of $0.30, which was in line with the Zacks Consensus Estimate but beat, by 30.4%, Q2 2025’s $0.23.
- Revenue of $243.6M, which beat the Zacks Consensus Estimate by 7.09% and, by 55.4%, Q2 2025’s $156.8M.
Management did not provide EPS and revenue guidance in its press release.
Chairman & CEO Sanj K. Patel commented: “In Q2, Kiniksa continued to drive growth in new and repeat prescribers of ARCALYST in recurrent pericarditis, which led to a meaningful increase in patients on therapy.
“As a result, we have raised our 2026 ARCALYST net sales guidance to between $980M and $995M.
“In our clinical portfolio, KPL-387 Phase 2 data supported initiation of the pivotal Phase 3 trial, PASTORALE, which is now enrolling and dosing patients.
“We are excited to advance KPL-387 with its target product profile of once-monthly subcutaneous dosing in a liquid formulation.
“We expect to bring this potential additional treatment option to patients in the 2028/2029 timeframe.
“Additionally, we continue to develop KPL-1161 with a target profile of once-quarterly dosing and are on track to initiate a Phase 1 trial by the end of this year.”
Eva Fortea Verdejo, a top 4% analyst from Wells Fargo maintains KNSA with a strong buy rating and raises their KNSA price target from $57.00 to $74.00, on Jul 13, 2026.
You can dive deeper into what analysts are forecasting on the Kiniksa Pharmaceuticals International stock forecast page.
KNSA Momentum
KNSA Growth Numbers
Last year, KNSA earnings were $109.57M. Over the past four year, KNSA's earnings have increased by -8.72% per year. This was slower than the Biotechnology industry average of 41.48%.
Last year, KNSA revenue was $945.96M. During the last five year, KNSA's revenue has increased by 116.69% per year. This was faster than the Biotechnology industry average of 30.09%.
Dig into KNSA's earnings and revenue performance here.
What are KNSA insiders up to?
In the past year, insiders at KNSA have sold more shares than they have bought.
Michael R. Megna, CAO of KNSA, was the latest KNSA insider to sell. They sold $369,380.00 worth of KNSA stock on Sep 3, 2026.
Dig into more about who owns KNSA stock here.
Can I get consistent income from KNSA stock?
No, Kiniksa Pharmaceuticals International doesn't provide an income stream by paying out dividends.
KNSA Social Trading Data
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other community members have to say.
Step 5: Place your KNSA purchase
You have two main options:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are usually sufficient. - Limit order: A limit order is an order to buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a specific price, use a limit order.
Hit the Open button and eToro will execute the order.
If you need more assistance buying stocks on eToro, click the helpful video below:
Step 6: Keep tabs on your KNSA investment
Now that you own some KNSA shares, you'll want to stay up-to-date on your new shares.
Start a watchlist to keep tabs on your KNSA stock.
KNSA Feed
How to Buy Stock in Kiniksa Pharmaceuticals International
To summarize, here are the 6 steps to buy stock in Kiniksa Pharmaceuticals International:
- Choose where to buy Kiniksa Pharmaceuticals International stock
- Open your brokerage account
- Deposit money your investment account
- Evaluate Kiniksa Pharmaceuticals International stock
- Place your KNSA purchase
- Keep tabs on your KNSA investment
If you require a brokerage, eToro is our recommended venue.
Get Started with eToro TodayIf you want to monitor your investment in Kiniksa Pharmaceuticals International, hit the button below to create your watchlist.
More Stock Buying Guides You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.